United States of America
Status: affected by circulating vaccine-derived poliovirus type 2 (cVDPV2)
Following the isolation of vaccine-derived poliovirus type 2 (VDPV2) in New York in July 2022, further virological and epidemiological analysis confirms circulation of this strain.
New York and US public health authorities continue to implement a timely and appropriate response to this circulating VDPV2 (cVDPV2), in order to rapidly interrupt its circulation, including by: continuing to intensify surveillance efforts (including for potential cases of paralysis), identifying population sub-groups/areas with potential immunity gaps, and proactively reaching out to communities with known immunity gaps to strengthen vaccination coverage.
Polio this week in United States of America
- No case of circulating vaccine-derived poliovirus type 2 (cVDPV2) was reported this week. One cVDPV2 case was reported in New York last week making it the first in the country. The case had onset of paralysis on 20 June, and had already previously been publicly reported (see link).
International Health Regulations
Countries affected by poliovirus circulation are subject to temporary recommendations issued by the Emergency Committee of the International Health Regulations on Poliovirus, under the auspices of the Public Health Emergency of International Concern. The latest report by the Committee is as of June 2022.
WHO’s International Travel and Health recommends that all travellers to polio-affected areas be fully vaccinated against polio. Residents (and visitors for more than 4 weeks) from infected areas should receive an additional dose of OPV or inactivated polio vaccine (IPV) within 4 weeks to 12 months of travel.